STING, RIG-I and NLRP3 agonists might increase the effectiveness of immuno-oncology checkpoint inhibitors, while antagonists of these targets offer an anti-inflammatory bonus.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Can innate immune system targets turn up the heat on 'cold' tumours?. Nat Rev Drug Discov 17, 3–5 (2018). https://doi.org/10.1038/nrd.2017.264
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd.2017.264
This article is cited by
-
Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer
Biomarker Research (2025)
-
Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody–STING agonist conjugates
Nature Biomedical Engineering (2025)
-
Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy
Cancer Immunology, Immunotherapy (2024)
-
Chemically programmed STING-activating nano-liposomal vesicles improve anticancer immunity
Nature Communications (2023)
-
The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING–IFN-β pathway
Nature Immunology (2021)
